Aims
-
Identify actionable molecular targets using bioinformatics, biobanking, and advanced molecular profiling.
-
Develop novel therapeutics and diagnostic technologies to optimize treatment selection and overcome therapeutic resistance.
-
Design and conduct precision cancer medicine clinical trials that translate molecular discoveries into improved patient care.
The Precision Cancer Medicine and Investigational Therapeutics (PCMIT) Program advances treatments guided by the molecular features of each cancer. Through bioinformatics, biobanking, and advanced molecular profiling, our members discover actionable biomarkers that inform therapy selection. We support team science that advances the development of targeted and mechanism‑based treatments aligned with individual patient needs.
A major emphasis of the program is translating these discoveries into the clinic. PCMIT leads trials that test new targeted therapies, immunotherapies, and hormone‑based treatments, supported by specialized resources such as precision pathology platforms and integrated clinical research infrastructure. These trials connect laboratory insights with patient care and help refine diagnostics, reduce reliance on invasive procedures, and overcome resistance. Through its combined focus on discovery, technology development, and clinical innovation, PCMIT strengthens the path from molecular insight to improved therapeutic options for individuals with cancer.
